Ikena Oncology (IKNA) 2021年年度报告「NASDAQ」.pdf

1、 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549 FORM 10-K (Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31,2021OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF

2、 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40287 IKENA ONCOLOGY,INC.(Exact name of Registrant as specified in its charter)Delaware81-1697316(State or other jurisdiction ofincorporation or organization)(I.R.S.EmployerIdentification No.)645 Summer Street,Suite 101Boston,MA02210

3、(Address of principal executive offices)(Zip Code)Registrants telephone number,including area code:(857)273-8343 Securities registered pursuant to Section 12(b)of the Act:Title of each class TradingSymbol(s)Name of each exchange on which registeredCommon Stock,par value$0.001 per share IKNA The Nasd

4、aq Global MarketSecurities registered pursuant to Section 12(g)of the Act:NoneIndicate by check mark if the Registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.YES NO Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 o

5、r 15(d)of the Act.YES NO Indicate by check mark whether the Registrant:(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12 months(or for such shorter period that the Registrant was required to file such reports),and(2)has

6、 been subject to such filing requirements for the past 90 days.YES NO Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(232.405 of this chapter)during the preceding 12 months(or for s